Given the challenges of running an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer's top vaccine executive hopes that regulators will allow an immunogenicity study for approval ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer rises after a study found that the company's new mRNA flu vaccine outperforms traditional shots against predominant strains.

MANILA (Reuters) - The Philippines' Food and Drug Administration has authorised for emergency use the COVID-19 vaccine developed by Pfizer and BioNTech, the first to be approved in the country, which ...

Pfizer may be one of the biggest bargains in the market today. The drugmaker offers an attractive yield, a rock-bottom valuation, and an underappreciated cancer pipeline. Long-term investors shouldn't ...

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

US pharma giant Pfizer has provided a reminder of the merits of mRNA-based vaccines as health leaders in the USA continue to question their safety.